scPharmaceuticals to Present in Two Upcoming Investor Conferences

February 25, 2021 8:00 AM EST
Get Alerts SCPH Hot Sheet
Price: $6.76 +0.60%

Overall Analyst Rating:
    BUY (= Flat)

Trade Now! 
Join SI Premium – FREE

News and research before you hear about it on CNBC and others. Claim your 1-week free trial to StreetInsider Premium here.

BURLINGTON, Mass., Feb. 25, 2021 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of infused therapies, advance patient care, and reduce healthcare costs, today announced that John Tucker, president & chief executive officer, will participate in two upcoming investor conferences.


Cowen 41st Annual Healthcare ConferenceThursday, March 410:30am EDT

H.C. Wainwright Global Life Sciences ConferenceTuesday, March 9 – Wednesday, March 10 A webcast of Mr. Tucker’s presentation will be available on-demand as of 7am ET, Tuesday, March 9

A live webcast of both presentations can be accessed under “News & Events” in the Investor Relations section of the Company’s website,

About scPharmaceuticals scPharmaceuticals is a pharmaceutical company focused on developing and commercializing products that are designed to reduce healthcare costs and improve health outcomes. The Company develops, internally and through strategic partnerships, innovative products and solutions that aim to expand and advance the outpatient care of select acute conditions. The Company’s lead programs focus on the subcutaneous, self-administration of IV-strength treatments in heart failure and infectious disease. scPharmaceuticals is headquartered in Burlington, MA. For more information, please visit

Katherine TaudvinscPharmaceuticals Inc.,

Investors:Hans VitzthumLifeSci Advisors,

Primary Logo

Source: scPharmaceuticals, Inc.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Globe Newswire, Press Releases

Related Entities

Cowen & Co, H.C. Wainwright